FOLH1 and prostate cancer: In our preliminary studies, we also developed targeted nanobubbles with an average diameter of 644.30±55.85 nm that carried monoclonal antibodies against prostate-specific membrane antigen (PSMA) and investigated the imaging potential of these nanobubbles in prostate cancer xenografts in nude mice.